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Application of Liquid Biopsies in Cancer
Targeted Therapy
S Sumanasuriya1,2, MB Lambros1 and JS de Bono1,2
As a growing body of evidence demonstrates intertumoral
and intratumoral heterogeneity and clonal evolution, both
during carcinogenesis and also throughout treatment
resulting in acquired drug resistance, the utility of blood-
based assays or “liquid biopsies” is becoming increasingly
recognized in clinical practice and trial design. “Liquid
biopsies” provide a less invasive approach to the current gold
standard of interrogating tumors by tissue biopsies, which
are frequently unfeasible, associated with morbidity, and
cannot be performed as often.
Over the past several years, two main forms of “liquid biopsy”
have emerged:
1. Circulating (plasma) cell free (cf) nucleic acids, including
DNA (cfDNA) shed by tumor cells into blood, and usually it
is probably encapsulated in some way, such as with exosomes,
cell fragments, or microparticles;
2. Circulating tumor cells (CTCs), intact rare cells found in
blood, which can be separated and counted as well as genomi-
cally characterized.
These two main types of analyses provide complementary
information; cfDNA is unable to characterize intrapatient het-
erogeneity at a single time point as well as single CTC analyses,
but acquiring cfDNA for analysis is more easily feasible in the
majority of patients with advanced cancer. Methods of increas-
ing CTC capture and improving cfDNA analyses are now
transforming this ﬁeld. Other types of circulating biomarker
analyses key to cancer medicine include whole blood transcrip-
tome analyses and circulating immune and endothelial cell
characterization that may shed light on tumor-stromal cell
interactions.
CIRCULATING NUCLEIC ACIDS
DNA, mRNA, and microRNA (miRNA) are shed into the blood
of patients with cancer from both primary and metastatic disease
sites through necrosis, apoptosis, and probably active release.
Cell-free DNA
The cfDNA concentrations vary considerably between patients
and tumor types; for example, glioblastoma and ovarian cancer
frequently have lower cfDNA levels, likely due to their disease
localization and pattern of spread. Quantitative and qualitative
analyses carried out on cfDNA have demonstrated utility as a
prognostic, predictive, and response biomarker. Studying cfDNA
has the ability to interrogate disease clonal evolution and resis-
tance mechanisms in serial and disease progression samples.
CfDNA detection can also be used to identify minimal residual
disease and early relapse, with array comparative genomic hybridi-
zation (aCGH) carried out on plasma cfDNA being comparable
to aCGH on the same patient tissue samples (see Figure 1a).
We have recently shown, for example, that decreases in cfDNA
concentrations and mutation allele frequency from baseline signiﬁ-
cantly associate with response to treatment with poly ADP-ribose
polymerase inhibition in advanced prostate cancer. Plasma cfDNA
analyses have been used to identify second hit mutations in BRCA2
and PALB2 restoring DNA repair gene function as mechanisms of
resistance to treatment at progression.1 Despite showing promise as a
biomarker from a liquid biopsy, cfDNA analyses are not currently
used routinely in clinical practice. However, in nonsmall cell lung
cancer, the US Food and Drug Administration has approved plasma
epidermal growth factor receptor testing from cfDNA for the pres-
ence of a T790M mutation, which can be used to detect acquired
resistance to ﬁrst and second generation tyrosine kinase inhibitors
(e.g., erlotinib and naratanib) but also confer sensitivity to third
generation tyrosine-kinase inhibitors, such as osimertinib.
Dilution by normal DNA can complicate and limit cfDNA anal-
yses but DNA stability in the circulation can allow tumor genomic
characterization by targeted, exome, and whole genome sequencing.
Orthogonal assays, such as digital droplet polymerase chain reaction
and aCGH, can also be used and provide analytic validation.
RNA and microRNAs
RNA is generally unstable in blood, but miRNA comprises stable,
short, noncoding molecules made of 9–25 nucleotides. Tumor-
derived miRNA is detectable in plasma, serum, urine, and even
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saliva and semen. These miRNAs can be analyzed by targeted or
RNA sequencing methods, with miRNA signatures identiﬁed as
signiﬁcantly deregulated in patients with cancer compared with
healthy volunteers, perhaps leading to utility in cancer diagnosis.
MiRNA signatures have been reported to be response biomarkers
for chemotherapy and radiotherapy, although reproducibility
remains a challenge. Additional studies are warranted to further
study the role of miRNA signatures for disease detection, prognos-
tication, identiﬁcation of minimal residual disease, tumor recur-
rence, and as a response biomarker.
Tumor educated platelet mRNA
Reports indicate, but need validation, that we may also be able to
acquire data from noncancer-derived cells, including tumor
educated platelets. Tumor cells are hypothesized to interact with
circulating platelets, “educating” them by activating surface recep-
tors and altering cytokine expression and altering platelet
mRNA. Investigating the mRNA proﬁles of tumor educated
platelets may provide information on cancer type, and work is
ongoing to validate these data.
CIRCULATING TUMOR CELLS
These are rare cells found in the blood of patients with cancer,
detectable at 1 CTC2,3 per milliliter or less of blood in patients
with advanced cancer. Precise identiﬁcation of these rare cells is
difﬁcult; the only US Food and Drug Administration cleared
platform for identifying CTCs remains the CellSearch platform
that identiﬁes CTCs based on epithelial cell adhesion molecule
capture and cytokeratin-positivity and CD-45 negativity. Multi-
ple other CTC assays have, however, been reported with different
degrees of analytic validation and clinical qualiﬁcation pursued to
date. CTC counts are highly prognostic, serve as post-treatment
response measures associating with survival, and may be true sur-
rogate biomarkers of treatment beneﬁt. Molecular characteriza-
tion of CTCs allows better insight into tumor heterogeneity
than cfDNA, with single cells being amenable to most assays,
including immunoﬂuorescence, array CGH, next generation
sequencing of both DNA and RNA, and ﬂuorescence in situ
hybridization. These may have clinical utility for use in trials for
patient selection, pharmacodynamics, and response biomarkers.
One major limitation, however, of CTC analyses has been the
very small numbers of cells generally captured from these studies.
We have recently demonstrated that identiﬁed and captured
CTC numbers can be enriched easily and safely using diagnostic
leukapheresis over 1–3 h.4 This procedure is well tolerated, with
the increased CTC yield allowing the genomic analyses of many
pure single CTCs and the study of intrapatient CTC genomic
heterogeneity. We have shown that, although these CTC analyses
are comparable to tumor biopsy genomics, biopsy analyses, which
usually analyze millions of cells, frequently miss the heterogeneity
identiﬁed in the study of many single CTCs4 (see Figure 1b).
Further prospective trials evaluating CTC enumeration as a
surrogate biomarker of response in prostate cancer are currently
being undertaken (TOPARP-B: ISRCTN15124653, CTC-STOP:
Figure 1 Array comparative genomic hybridization (aCGH) performed on plasma cell-free DNA (a) and on multiple circulating tumor cells (CTCs) (b),
reflecting intrapatient heterogeneity compared to aCGH on diagnostic tumor samples.
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ISRCTN82499869) as are trials incorporating techniques to maxi-
mize CTC yield in order to fully realize the full potential of CTCs
as multipurpose biomarkers.
IMMUNE CELL STUDIES
Neutrophil-to-lymphocyte ratio
An inexpensive, easily available, but nonspeciﬁc assay, an immune
cell study5 has previously been documented to be a highly
prognostic factor in studies of >50,000 patients with cancer with
many solid tumors. This inexpensive biomarker of cancer
inﬂammation can predict likelihood of response to treatment,
associating with response to abiraterone and taxanes in advanced
prostate cancer. Signiﬁcant changes in neutrophil-to-lymphocyte
ratio (NLR) during treatment also correlate with response.
High NLR levels may correlate with increased myeloid-derived
suppressor cell (MDSC) counts.
Myeloid derived suppressor cells
These originate from primitive hematopoietic precursors as a
result of tumor-generated endocrine and paracrine factors, and
can be immunosuppressive and support tumor growth, survival,
and treatment resistance. High MDSC levels correlate not only
with high NLR levels but also with decreased response to treat-
ment and shorter survival. Peripheral MDSC subsets have been
identiﬁed and these can be sorted by ﬂow cytometry, and the
proteins they release studied ex vivo. Studies into MDSC subsets
and their cytokine release may help direct anticancer treatment.
CONCLUSION
Circulating biomarkers may aid diagnosis, prognostication, identify
minimal residual disease, and allow disease molecular
characterization, with serial sample analyses allowing response assess-
ment, clonal evolution, and studies of therapeutic resistance. Circu-
lating tumor cells and cfDNA are complementary noninvasive
approaches for such biomarker studies. We envision that rigorous
validation, including healthy volunteer blood analyses studies and
prospective clinical trials for clinical qualiﬁcation, will allow these
biomarkers to transform cancer care.
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